-+ 0.00%
-+ 0.00%
-+ 0.00%

Pentixapharm Reports Data Supporting Phase 3 PANDA Study in Primary Aldosteronism

PUBT·10/19/2026 06:31:19
Listen to the news
Pentixapharm Reports Data Supporting Phase 3 PANDA Study in Primary Aldosteronism
  • Pentixapharm highlighted data being presented at EANM 2026 supporting its planned Phase 3 PANDA trial of Pentixafor PET/CT in primary aldosteronism.
  • Independent studies suggest the scan can identify one-sided disease suitable for surgery, potentially reducing reliance on invasive adrenal vein sampling.
  • PANDA will evaluate noninvasive subtyping in adults with confirmed primary aldosteronism; preparations for the U.S.-centric trial are progressing.
  • The FDA cleared the trial to proceed in June 2026, granting Fast Track designation for the indication in July 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pentixapharm Holding AG published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2417616_en) on October 19, 2026, and is solely responsible for the information contained therein.